NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Quantum BioPharma's Private Placement of Class A Multiple Voting Shares
TL;DR
Quantum BioPharma's private placement restores key investors' voting control to 75.27%, providing strategic advantage for advancing neurodegenerative and metabolic disorder treatments.
Quantum BioPharma will issue 30 Class A shares at $25 each to raise $750,000 for working capital, approved by shareholders on September 26, 2025.
This funding supports Quantum BioPharma's development of treatments for multiple sclerosis and alcohol misuse disorders, potentially improving patient outcomes worldwide.
Quantum BioPharma's Lucid-MS compound reverses myelin degradation in preclinical models, representing a novel approach to treating multiple sclerosis.
Found this article helpful?
Share it with your network and spread the knowledge!
Quantum BioPharma announced a non-brokered private placement of up to 30 Class A multiple voting shares at $25 per share for gross proceeds of up to $750.
The offering will increase voting rights attached to the Class A shares to 75.27%, restoring them to nearly their original level when the company went public in 2018, and provides working capital for the company.
The offering is expected to be fully subscribed by entities controlled by Zeeshan Saeed and Anthony Durkacz.
The offering was approved by shareholders on September 26, 2025.
Proceeds will be used for general working capital purposes.
Quantum BioPharma is dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders.
Through its subsidiary Lucid Psycheceuticals, Quantum BioPharma is developing Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models.
Quantum BioPharma retains ownership of 20.11% of Unbuzzd Wellness Inc. and receives royalty payments of 7% of sales from unbuzzd™ until payments total $250 million, after which the royalty drops to 3% in perpetuity.
The latest news and updates relating to QNTM are available in the company's newsroom at https://www.investorbrandnetwork.com/clients/quantum-biopharma-ltd/
Quantum BioPharma maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.
Curated from InvestorBrandNetwork (IBN)
